Hemolytic-Uremic Syndrome in France. 2023 Report.

Key Points

  • In 2023, the annual incidence of pediatric HUS was lower than in 2022 (a year marked by a particularly high incidence linked to the occurrence of several outbreaks). It was once again comparable to the incidence rates observed between 2017 and 2021.

  • Variations in regional incidence rates are observed each year. A study by Santé publique France published in 2023 demonstrated geographic disparities in the risk of sporadic pediatric HUS (not linked to an outbreak).

  • In 2023, serogroup O26 remained the most prevalent.

In relation to

Our latest news

news

Shamonda Virus: First Human Case Detected in France—What Do We Know?

news

Call for Nominations for the Renewal of the Scientific Advisory Board of the...

news

Growing Up with Screens. A special report in *La Santé en action* No. 474,...